Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024312 (
lymphopenia
)
4,859
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Helper versus cytotoxic T lineage decision in the thymus has been studied as a model for silencing of alternative lineage genes. Although the transcription factor RUNX3 is required for the initiation of
Cd4
silencing in developing CD8 T cells, it is unknown how silencing of
Cd4
and other helper T lineage genes is maintained. We show that the histone methyltransferase
G9a
is necessary for silencing helper T lineage genes in proliferating mouse CD8 T cells. Despite normal initial
Cd4
downregulation,
G9a
-deficient CD8 T cells derepress
Cd4
and other helper lineage genes during repeated division in
lymphopenia
or in response to tumor Ag. However,
G9a
was dispensable for continued silencing of those genes in CD8 T cells that respond to infection by
Listeria monocytogenes
These results demonstrate that
G9a
facilitates maintenance of cellular identity of CD8 T cells during cell division, which is further reinforced by inflammatory signals.
...
PMID:Cutting Edge: The Histone Methyltransferase G9a Is Required for Silencing of Helper T Lineage-Associated Genes in Proliferating CD8 T Cells. 2972 Apr 23
Hyperinflammation and
lymphopenia
provoked by SARS-CoV-2-activated macrophages contribute to the high mortality of Coronavirus Disease 2019 (COVID-19) patients. Thus, defining host pathways aberrantly activated in patient macrophages is critical for developing effective therapeutics. We discovered that
G9a
, a histone methyltransferase that is overexpressed in COVID-19 patients with high viral load, activates translation of specific genes that induce hyperinflammation and impairment of T cell function or
lymphopenia
. This noncanonical, pro-translation activity of
G9a
contrasts with its canonical epigenetic function. In endotoxin-tolerant (ET) macrophages that mimic conditions which render patients with pre-existing chronic inflammatory diseases vulnerable to severe symptoms, our chemoproteomic approach with a biotinylated inhibitor of
G9a
identified multiple
G9a
-associated translation regulatory pathways that were upregulated by SARS-CoV-2 infection. Further, quantitative translatome analysis of ET macrophages treated progressively with the
G9a
inhibitor profiled
G9a
-translated proteins that unite the networks associated with viral replication and the SARS-CoV-2-induced host response in severe patients. Accordingly, inhibition of
G9a
-associated pathways produced multifaceted, systematic effects, namely, restoration of T cell function, mitigation of hyperinflammation, and suppression of viral replication. Importantly, as a host-directed mechanism, this
G9a
-targeted, combined therapeutics is refractory to emerging antiviral-resistant mutants of SARS-CoV-2, or any virus, that hijacks host responses.
...
PMID:Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics. 3323 14